VTDigger
16/11/2026 17:43

Forced drug switches are burying clinics in paperwork

Text reading "Commentaries" and "Opinion pieces by community members" with a speech bubble icon.

This commentary is by Teresa Fama, a practicing rheumatologist at University of Vermont Health. 

Vermont and the nation are struggling with how to reduce healthcare costs. Much of the increase is due to prescription drugs and labor, particularly as the latter makes up 65% of UVM Health’s total expenses. To highlight the compounding effect on costs from these two aspects of healthcare, let’s look at Vermont’s Act 193.

Vermont’s Act 193 requires pharmacists to dispense the lowest-priced interchangeable biologic medication to patients. These interchangeable biologic medications are biosimilars of the reference product, meaning they are highly similar with no clinically meaningful differences in safety, purity or potency — think similar to “generic.” Act 193 was enacted in 2018 when not many biosimilars were available. For example, Humira, the most prescribed biologic to treat rheumatoid arthritis, had three biosimilars approved in 2018. Today, there are 10. 

Act 193 was intended to reduce the cost of healthcare by reducing prescription drug prices. And indeed, a national analysis of Medicare data found that each new biosimilar on the market is associated with a 10% to 13% drop in the price of the brand-name drug. This analysis, however, does not consider consequences for patients and the administrative costs to the healthcare system.

Switching medication based on formulary and not on treatment failure can cause harm to patients. As the number of biologics and biosimilars has increased, insurance companies’ formularies change based on deals with pharmacy benefit managers, often resulting in patients’ having to change medication every year. As a rheumatologist who prescribes biologic medications for inflammatory autoimmune diseases such as rheumatoid arthritis, I find it’s not uncommon for patients to have tried a few biologics before finding the one that works for their condition. Once patients are on a biologic that works, having them switch again creates enormous undue stress and often patient suffering. 

READ MORE

Switching also creates high costs for healthcare clinics, and subsequently the healthcare system, due to a significant increase in prior authorizations, where the burden is on the clinic to process the paperwork. An increase in prior authorizations increases the time for clinicians to review and, in some cases, appeal a prior authorization decision; it also generates more phone calls from patients and office visits. Our clinical pharmacists and nurses, along with members of a prior authorization team, spend a significant amount of time on phone calls or processing paperwork pursuing prior authorizations and appeals. We would rather clinical pharmacists and nurses spend most of their time on patient education, clinician assistance and education, and medication protocols.

As many of these biosimilars are considered interchangeable and have been shown to work similarly to the reference product  — for example, Yuflyma is considered interchangeable with Humira, according to the Food and Drug Administration — the biosimilar should be exempt from the standard prior authorization protocols for the reference product. In other words, if Humira had been approved in the past, then a prior authorization for Yuflyma should not be required. However, we find that these drugs are treated as stand-alone and are subjected to the same cost tier, even though they are supposedly cheaper, and regularly prompt prior authorizations. 

And in some cases, we’re often told that a patient must fail on a certain number of biosimilars before they can return to the reference product. In essence, step therapy — an insurer requirement that patients try and fail on cheaper drugs before coverage of the prescribed one — has been created for biosimilars despite them being interchangeable, a process not originally intended for biosimilars.  

What can be done? The Vermont Legislature should reconsider mandating that patients switch to biosimilars in the absence of treatment failure. Treat interchangeable drugs as intended, thus barring practices such as standard prior authorization protocols and step therapy. Follow the money — investigate who is really benefiting from these practices, as it is not obvious that patients are — and quantify the administrative costs to our healthcare system.

Read the story on VTDigger here: Forced drug switches are burying clinics in paperwork.

📄 Contenido indexado automáticamente. No es de autoría de altabusqueda.com; los derechos pertenecen a su fuente: VTDigger.
Ver nota original ↗
🤖 Profundizá esta noticia con OIMA (IA)

¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?

Respuestas de OIMA · IA, sobre esta noticia · Abrir OIMA Chat ↗
💬 0

Comentarios

También te puede interesar

Dismissed Bennington County murder case heads back to court
VTDigger
The suspect is currently in custody serving a 12½-year prison sentence on federal drug and firearm charges. R…
Montpelier appoints new police chief
VTDigger
Burlington’s current deputy police chief is becoming Montpelier’s police chief in January. Read the story on …
State help for flood survivors was disorganized and slow to arrive. For some, it never came.
VTDigger
“A lot of folks simply were out of luck.” Read the story on VTDigger here: State help for flood survivors was…
Vermont Senate Democrats nominate Andrew Perchlik to be chamber’s next leader
VTDigger
Since Democrats will control a supermajority of seats in the chamber, their choice for the president pro temp…
Barre City Mayor Thom Lauzon dies
VTDigger
Lauzon was elected earlier this year to his eighth term in office. Read the story on VTDigger here: Barre Cit…
Spend our tax dollars on healthcare, not pricey consultants
VTDigger
Nearly six years after McKinsey settled with Vermont over its role in the opioid crisis, the state is handing…